{"a":[{"_":"Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination","$":{"href":"/biotech/merck-posts-then-pulls-trial-plan-pd-1xvegf-and-trop2-adc-combination","hreflang":"en"}}]}

Summary

Merck briefly disclosed plans for a clinical trial combining its PD-1xVEGF bispecific antibody with a TROP2 ADC before removing the information. The company had not previously disclosed concrete details about the intended use of its PD-1xVEGF program.